Michael W Deininger

 Michael Deininger, MD, PhD
Max S Wicha M.D. Distinguished Professor of Oncology
Professor of Internal Medicine
Deputy Director, Rogel Cancer Center
Section Head, Internal Medicine, Medical School
Office:
Rogel Cancer Center
Rogel Cancer Center, Room 7215
1500 E Medical Center Dr
Ann Arbor, MI 48109-5948
Available to mentor
Michael W Deininger
Michael Deininger, MD, PhD
Professor
  • About
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications

  • Manage Your Profile

    • About

    The Deininger lab expertise is in the translational research of leukemia. The lab's research program focuses on the biology of myeloproliferative neoplasms and the development of molecular targeted therapies.

    Qualifications
    • Hematology and Bone Marrow Transplant Fellowship: Department of Hematology
      University of Leipzig, Germany
      1999 - 2001
    • PhD
      Imperial College, Department of Hematology, Hammersmith Hospital, United Kingdom
      1995 - 1999
    • Internal Medicine Residency and Hematology/Oncology Fellowship:
      Institute of Medical Oncology and Hematology Nürnberg General Hospital, Germany
      1992 - 1995
    • Internship
      Marienhospital Aachen, Germany
      1990 - 1992
    • MD
      University of Würzburg Medical School, Germany
      1984 - 1990
    • MD
      University of Regensburg Medical School, Germany
      1982 - 1984

    Center Memberships
    • Center Member
      Rogel Cancer Center

    Research Overview

    The Deininger lab’s expertise focuses on translational research in leukemia, specifically the biology of myeloproliferative neoplasms and the development of molecular targeted therapies. We are especially interested in developing novel, anti-neoplastic targeted therapies in myeloid leukemia, as well as understanding the molecular mechanisms of cancer stem cell persistence and leukemia drug resistance.
    Our lab orchestrates a multidisciplinary cancer research program, straddling genetics, biochemistry, molecular biology, pharmacology and biomedical engineering. We are proud of our vibrant team of scientists who strive to improve the diagnosis, deep analysis and therapeutics of myeloid leukemia.

    Recent Publications

     See All Publications
    • Journal Article
      Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors
      Tantravahi SK, Ellero AA, Patel AB, Parsegov B, Walker CJ, Yap JT, Boucher KM, Rets AV, Prchal JT, Deininger MW. Blood Cancer Journal, 2026 Dec 1; 16 (1): DOI:10.1038/s41408-026-01571-2
      PMID: 42477316
    • Journal Article
      Single-cell RNA editing identifies aggressive and favorable cellular states in chronic myelomonocytic leukemia.
      Wickramasinghe N, Bui D, Neupane S, Ferrall-Fairbanks MC, Deininger MM, Padron E, Gu T. Haematologica, 2026 Sep 3; DOI:10.3324/haematol.2026.301007
      PMID: 42687821
    • Journal Article
      Asciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results
      Cortes JE, Rea D, Mauro MJ, Hochhaus A, Kim DW, Sasaki K, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, Gómez García de Soria V, le Coutre P, Mahon FX, DeAngelo DJ, Damon A, Kapoor S, Sanchez-Olle G, Hoch M, Agrawal N, Quenet S, Hughes TP. Leukemia, 2026 Sep 1; 40 (9): 1893 - 1900. DOI:10.1038/s41375-026-02972-9
      PMID: 42463944
    • Journal Article
      Five-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial
      Kantarjian H, Deininger M, Apperley JF, Arthur CK, Chuah C, Hochhaus A, de Lavallade H, Lipton JH, Lomaia E, McCloskey J, Maness L, Mauro M, Moiraghi B, Pavlovsky C, Rosti G, Rousselot P, Chao B, Vorog A, Reddick LE, Patel N, Hennessy M, Yeh T, Cortes J. Leukemia, 2026 Sep 1; 40 (9): 1882 - 1892. DOI:10.1038/s41375-026-03009-x
      PMID: 42498834
    • Journal Article
      Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study
      Gotlib J, Reiter A, Radia DH, Álvarez-Twose I, Deininger MW, George TI, Panse J, Mital A, Pettit KM, Vannucchi AM, Platzbecker U, Hermine O, Elshoury A, Livideanu CB, Mesa R, Ustun C, Triggiani M, Dybedal I, Jurcic JG, Zanotti R, Oh ST, Yacoub A, Hexner EO, Bose P, Lee SG, Sperr WR, Griffiths EA, Butler M, Lübke J, Bidollari I, Lin HM, Rylova S, Dimitrijević S, Muñoz-González JI, DeAngelo DJ. Blood Advances, 2026 May 26; 10 (10): 3676 - 3689. DOI:10.1182/bloodadvances.2025017519
      PMID: 41604606
    • Journal Article
      Intrinsic Cellular Resistance to BCR::ABL1 Inhibitors
      Cruz-Rodriguez N, Torres-Llanos Y, Deininger M. Haematologica, 2026 Jan 1; 111 (7): 2244 - 2265. DOI:10.3324/haematol.2025.287814
      PMID: 41676916
    • Journal Article
      KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis
      Reiter A, Rossignol J, Deininger MW, Luebke J, Hermine O, Akin C, Gotlib J, Radia DH. Journal of Allergy and Clinical Immunology in Practice, 2026 Jan 1; 14 (1): 44 - 52. DOI:10.1016/j.jaip.2025.10.034
      PMID: 41187902
    • Journal Article
      Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results
      Hochman MJ, Ruppert AS, Huang Y, Mims A, Borate U, Swords R, Traer E, Baer MR, Duong VH, Stock W, Odenike T, Patel P, Madanat Y, Stein E, Deininger MW, Schiller G, Pollyea DA, Foran JM, Olin R, Lin T, Boyiadzis MM, Handa S, Rueter B, Gana TJ, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus S, Rosenberg L, Druker B, Levine R, Burd A, Yocum AO, Byrd JC, Blum W. Haematologica, 2026 Jan 1; DOI:10.3324/haematol.2026.300627
      PMID: 42021690